Advancing science as a biotechnology company rarely goes exactly as planned, and Zynerba Pharmaceuticals (ZYNE) is no exception. When they reported data from their pivotal CONNECT-FX trial, the market's reaction was harsh, with the stock dropping 50%. CONNECT-FX studied Zynerba's lead compound, Zygel, in 212 patients with Fragile X Syndrome (FXS). Zygel is a synthetic CBD gel that is rubbed into the upper arm of patients. The study missed the primary and secondary endpoints in the full analysis set, and while this is a disappointment, there is a significant silver lining. In a